Weaning Strategy of Diuretics in Outpatient Preterm Infants with Bronchopulmonary Dysplasia: A National Survey

Abstract

Objective Long-term diuretic treatment in patients with bronchopulmonary dysplasia (BPD) is common despite lack of data that support its use. We aimed to characterize the commonly used diuretics weaning strategies for outpatient clinically stable preterm infants with BPD.

Study Design We conducted a cross-sectional web-based survey among all pediatric pulmonologists and neonatologists in Israel. Questionnaire included data regarding practitioners' different diuretics-weaning practice in this population.

Results The response rate for pulmonologists and neonatologists were 35/50 (70%) and 36/120 (30%), respectively. When both oxygen and diuretics are used, 59% wean oxygen first and 32% wean diuretics first. If patients are solely on diuretics, 27% discontinue instantly, 34% decrease the dosage gradually, and 34% outgrow the discharge dosage. Significantly more pulmonologists decrease the dosage gradually, while more neonatologists discontinue at once (p < 0.001). Most participants (94%) reported being unsatisfied with the existing data and guidelines regarding these issues.

Conclusion Our results showed a wide range of practice patterns in the weaning strategy of diuretics in outpatient preterm infants with BPD. Pulmonologists and neonatologists differ significantly in their weaning strategy. A prospective larger controlled study to explore the outcome of gradual tapering versus discontinuation without weaning is warranted.

Key Points

• Diuretic treatment in patients with BPD is common despite lack of data that support its use.

• We demonstrated a wide range of practice patterns in the weaning strategy of diuretics in outpatients' BPDs.

• Pulmonologists and neonatologists differ significantly in their weaning strategy.

• Most participants are unsatisfied with the existing data and guidelines regarding these issues.

Keywords

diuretics - bronchopulmonary dysplasia - weaning

Publication History

Received: 04 May 2020

Accepted: 30 July 2020

Article published online:
06 September 2020

• References

• 1 Kraybill EN, Runyan DK, Bose CL, Khan JH. Risk factors for chronic lung disease in infants with birth weights of 751 to 1000 grams. J Pediatr 1989; 115 (01) 115-120
• 2 Sinkin RA, Cox C, Phelps DL. Predicting risk for bronchopulmonary dysplasia: selection criteria for clinical trials. Pediatrics 1990; 86 (05) 728-736
• 3 Isayama T, Lee SK, Yang J. et al. Canadian Neonatal Network and Canadian Neonatal Follow-Up Network Investigators. Revisiting the definition of bronchopulmonary dysplasia: effect of changing panoply of respiratory support for preterm neonates. JAMA Pediatr 2017; 171 (03) 271-279
• 4 Higgins RD, Jobe AH, Koso-Thomas M. et al. Bronchopulmonary dysplasia: executive summary of a workshop. J Pediatr 2018; 197: 300-308
• 5 Stoll BJ, Hansen NI, Bell EF. et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA 2015; 314 (10) 1039-1051
• 6 Ehrenkranz RA, Walsh MC, Vohr BR. et al. National Institutes of Child Health and Human Development Neonatal Research Network. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005; 116 (06) 1353-1360
• 7 Lapcharoensap W, Gage SC, Kan P. et al. Hospital variation and risk factors for bronchopulmonary dysplasia in a population-based cohort. JAMA Pediatr 2015; 169 (02) e143676
• 8 Iyengar A, Davis JM. Drug therapy for the prevention and treatment of bronchopulmonary dysplasia. Front Pharmacol 2015; 6: 12
• 9 Kao LC, Durand DJ, McCrea RC, Birch M, Powers RJ, Nickerson BG. Randomized trial of long-term diuretic therapy for infants with oxygen-dependent bronchopulmonary dysplasia. J Pediatr 1994; 124 (5 Pt 1): 772-781
• 10 Brion LP, Primhak RA, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2002; (01) CD001817
• 11 Stewart A, Brion LP, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2011; (09) CD001817
• 12 Stewart AL, Brion LP. Routine use of diuretics in very-low birth-weight infants in the absence of supporting evidence. J Perinatol 2011; 31 (10) 633-634
• 13 Ann R, Stark ECE. Bronchopulmonary dysplasia: management. Up To Date 2019
• 14 Duijts L, van Meel ER, Moschino L. et al. European Respiratory Society guideline on long term management of children with bronchopulmonary dysplasia. Eur Respir J 2019
• 15 Slaughter JL, Stenger MR, Reagan PB. Variation in the use of diuretic therapy for infants with bronchopulmonary dysplasia. Pediatrics 2013; 131 (04) 716-723
• 16 Greenberg JM, Poindexter BB, Shaw PA. et al. Respiratory medication use in extremely premature (<29 weeks) infants during initial NICU hospitalization: results from the prematurity and respiratory outcomes program. Pediatr Pulmonol 2020; 55 (02) 360-368
• 17 Bhandari A, Chow U, Hagadorn JI. Variability in duration of outpatient diuretic therapy in bronchopulmonary dysplasia: a clinical experience. Am J Perinatol 2010; 27 (07) 529-535
• 18 Ryan RM, Keller RL, Poindexter BB. et al. PROP Investigators. Respiratory medications in infants <29 weeks during the first year postdischarge: the Prematurity and Respiratory Outcomes Program (PROP) Consortium. J Pediatr 2019; 208: 148-155.e3
• 19 Beermann B, Dalén E, Lindström B. Elimination of furosemide in healthy subjects and in those with renal failure. Clin Pharmacol Ther 1977; 22 (01) 70-78
• 20 Ramanathan R. Pharmacology review. Bronchopulmonary Dysplasia Diuretics 2008; 9: e260-e7
• 21 Maitre NL, Ballard RA, Ellenberg JH. et al. Prematurity and Respiratory Outcomes Program. Respiratory consequences of prematurity: evolution of a diagnosis and development of a comprehensive approach. J Perinatol 2015; 35 (05) 313-321
• 22 Girardi A, Galletti S, Raschi E. et al. Pattern of drug use among preterm neonates: results from an Italian neonatal intensive care unit. Ital J Pediatr 2017; 43 (01) 37
• 23 Helenius K, Sjörs G, Shah PS. et al. International Network for Evaluating Outcomes (iNeo) of Neonates. Survival in very preterm infants: an International Comparison of 10 National Neonatal Networks. Pediatrics 2017; 140 (06) 140
• 24 Feltman DM, Du H, Leuthner SR. Survey of neonatologists' attitudes toward limiting life-sustaining treatments in the neonatal intensive care unit. J Perinatol 2012; 32 (11) 886-892